- Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURAGrohe, C.; Herbst, R. S.; Tsuboi, M.; John, T.; Majem, M.; Goldman, J. W.; Kim, S. -W.; Marmol, D.; Rukazenkov, Y.; Wu, Y. -L.; Engel-Riedel, W.
- Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURATsuboi, Masahiro; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan Wade; Kim, Sang-We; Marmol, Dominika; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 52
- Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated resultsLyu, C.; Fang, W.; Jiao, W.; Ma, H.; Wang, J.; Xu, S.; Wu, N.; Wang, R.; Yang, Y.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 7
会议论文
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
12被引9阅读
